MPV17L: A Potential Drug Target and Biomarker for Mitochondrial Disorders

Target Name: MPV17L

NCBI ID: G255027

MPV17L

MPV17L: A Potential Drug Target and Biomarker for Mitochondrial Disorders

Mitochondrial disorders are a group of genetic disorders caused by defects in the mitochondria, which are organelles responsible for generating energy in the cell. These disorders can lead to a range of symptoms, including muscle weakness, fatigue, cognitive impairments, and even death. MPV17L, a protein that is similar to mitochondrial membrane protein-like, has been identified as a potential drug target and biomarker for mitochondrial disorders. In this article, we will explore the biology of MPV17L and its potential as a drug target.

Biochemistry and Structure of MPV17L

MPV17L is a 21-kDa protein that is expressed in various tissues and organs, including muscle, heart, brain, and liver. It is a member of the superfamily of transmembrane protein (SMP), which includes other well-known proteins such as ion channels, G protein-coupled receptors, and intracellular signaling proteins. MPV17L has a unique structure that is similar to that of mitochondrial membrane protein-like (MMP), a protein that is expressed in high levels in the mitochondria and is involved in the regulation of mitochondrial dynamics and function.

Function and Significance of MPV17L

MPV17L is involved in a variety of cellular processes that are essential for proper mitochondrial function. One of its functions is to regulate the mitochondrial translocation of mitochondrial DNA (mtDNA) to the cytoplasm, which is necessary for the development and maintenance of new mitochondrial organelles. Additionally, MPV17L is involved in the regulation of mitochondrial fusion, which is the process by which new mitochondria are synthesized and inserted into the cytoplasm.

MPV17L has also been shown to play a role in the regulation of cellular metabolism and energy homeostasis. It is a known regulator of the mitochondrial ATPase, which is responsible for generating ATP energy in the cell. Additionally, MPV17L has been shown to interact with various nuclear and cytoplasmic proteins, including CoQ10, which is a key component of the mitochondrial electron transport chain.

Drug Target Potential

The potential drug targets for MPV17L are vast and varied. One of the primary targets is the regulation of mitochondrial dynamics, which is critical for the proper functioning of the mitochondria. Drugs that can modulate mitochondrial dynamics and function could potentially be effective in treating a variety of mitochondrial disorders. Additionally, MPV17L has been shown to play a role in the regulation of cellular metabolism and energy homeostasis, which could make it an attractive target for drugs that target energy metabolism.

Biomarker Potential

MPV17L has been shown to be expressed in various tissues and organs, including muscle, heart, brain, and liver, which makes it an attractive biomarker for a variety of mitochondrial disorders. Additionally, its unique structure and function make it a potential target for drugs that can modulate the structure and function of the mitochondria.

Conclusion

MPV17L is a protein that is expressed in various tissues and organs and is involved in a variety of cellular processes that are essential for proper mitochondrial function. Its unique structure and function make it a potential drug target and biomarker for mitochondrial disorders. Further research is needed to fully understand the biology of MPV17L and its potential as a drug target and biomarker.

Protein Name: MPV17 Mitochondrial Inner Membrane Protein Like

Functions: Isoform 1 participates in reactive oxygen species metabolism by up- or down-regulation of the genes of antioxidant enzymes

The "MPV17L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MPV17L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets